References
  1. Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol2019; 15:91-101.
  2. Chen M, Jayne DRW, Zhao MH. Complement in ANCA-associated vasculitis: mechanisms and implications for management. Nat Rev Nephrol2017; 13:359-67.
  3. Quintana LF, Kronbichler A, Blasco M, et al. ANCA associated vasculitis: The journey to complement-targeted therapies. Mol Immunol 2019; 112:394-8.
  4. Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014; 25:225-31.
  5. Hilhorst M, van Paassen P, van Rie H, et al. Complement in ANCA-associated glomerulonephritis. Nephrol Dial Transplant2017; 32:1302-13.
  6. Brilland B, Garnier AS, Chevailler A, et al. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. Autoimmun Rev 2020; 19:102424.
  7. Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.Arthritis Res Ther 2012; 14:R140.
  8. Gou SJ, Yuan J, Chen M, Yu F, Zhao MH. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2013; 83:129-37.
  9. Kronbichler A, Kerschbaum J, Gründlinger G, et al. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant 2016; 31:930-6.
  10. Antovic A, Mobarrez F, Manojlovic M, et al. Microparticles expressing myeloperoxidase and complement C3a and C5a as markers of renal involvement in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol 2020; 47:714‐21.
  11. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990; 33:1101-7.
  12. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222-7.
  13. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.
  14. Bajema IM, Hagen EC, Hansen BE, et al. The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant 1996; 11:1989-95.
  15. Berden AE, Ferrario F, Hagen EC, et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21:1628-36.
  16. Mahr A, Specks U, Jayne D. Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford)2019; 58:1707-9.
  17. Wu EY, McInnis EA, Boyer-Suavet S, et al. Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated Vasculitis.Arthritis Rheumatol 2019; 71:1894-903.
  18. Ling M, Murali M. Analysis of the complement system in the clinical immunology laboratory. Clin Lab Med 2019; 39:579-90.
  19. Gou SJ, Yuan J, Wang C, et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin J Am Soc Nephrol 2013; 8:1884-91.
  20. Jayne D. Complement inhibition in ANCA vasculitis. Nephrol Ther2019; 15:409-12.
  21. Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756-67.
  22. Li R, Coulthard LG, Wu MC, et al. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013; 27:855-64.